Los Angeles, CA, March 07, 2010 --(PR.com
)-- After a successful performance in the recently concluded year-long efficacy controlled trial, AVT-12, a combination drug product intended for weight loss, has been redesignated Obestrin® in preparation for the marketplace.
The name Obestrin® is particularly appropriate, given the new combination drug product’s connection with the GPR39 associated peptide obestatin.
Findings from the controlled trial suggest that Obestrin® may also confer additional health benefits extending beyond weight loss.
In the recent phase III trial, Obestrin® improved HDL/LDL ratios, as well as substantially improved serum levels of C-reactive protein, or CRP, a known predictive risk-factor in a variety of chronic illnesses.
Over the course of the 12 month trial, the percentage of participants in the lowest category of risk, based on CRP levels of less than 1 ng/mL, went from 9.3% to 44.7%, while the placebo control group’s levels remained unchanged.